Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

394P - Reversing the trend of Friday peak for metastatic spinal cord compression referrals

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Sola Adeleke

Citation

Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269

Authors

S.M. Adeleke1, W. Kinnaird2, R. Lin3, Y. Hu2, H.A. Payne2

Author affiliations

  • 1 Centre For Medical Imaging, Division Of Medicine, University College London, W1W 7TY - London/GB
  • 2 Radiotherapy Department, P-2 Basement Level, University College London Hospital - University College London Hospitals NHS Foundation Trust, NW1 2BU - London/GB
  • 3 Medical School, University College London, WC1E 6DE - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 394P

Background

Metastatic spinal cord compression (MSCC) is an oncological emergency which requires urgent treatment to prevent irreversible cord damage (1)(2). National Institute of Health and Care Excellence (NICE) recommends definitive treatment within 24hours of confirmed diagnosis (3).

Methods

To evaluate practice at our institute, analysis was carried out on referrals between 2014-2018, which includes 207 referrals with MSCC confirmed on imaging. Normality was assessed using Kolmogorov-Smirnov test. Kruskal-Wallis test was used to compare differences in referrals between days of the week.

Results

Commonest malignancies were sarcoma (25%), myeloma (18%), prostate (14%) & lung (11%). Previous data suggests prostate and lung cancers as commonest malignancies causing MSCC, accounting for over 50% of cases (4)(5). However, UCLH is a referral centre for sarcomas and hematological malignancies hence might explain numbers. We compared the referral numbers between Mondays and Fridays for all years combined (Table). More referrals were made on Wednesday through Friday with 57, 52 and 42 referrals respectively, p=0.134. There were less referrals on Saturday through Monday and even up to Tuesday as most referral decisions were made in the clinics. The numbers for Sunday through Tuesday were 5, 2, 21 and 28 respectively. Table: 394P

Shift in trend of referrals over three decades

Monday Tuesday Wednesday Thursday Friday Saturday Sunday
Number of referrals (2014-2018) 21 28 57 52 42 5 2
Percentage of referrals (2014-2018) 10% 14% 28% 25% 20% 2% 1%
Koiter E, 2013 (1998-2009) 11.6% 16.3% 18.4% 20.9% 26.3% 3.6% 3.1%
Poortsmans P, 2001(1987-1997) 12% 17% 15% 20% 30% 5% 1%

A build-up and then a Friday peak of MSCC referrals as previously reported by Poortmans and then Koiter between 1987-2009. However, our data (2014-2018) shows a shift away from the Friday peak over the past 5 years. This could mean improvement in care as previous data suggests ward rounds tend to occur before weekends when treatment decisions were sometimes made. Weekend referrals still remain low across the groups.

Conclusions

The Wednesday to Friday pattern described shows a potential shift away from the ‘Friday peak’ (6)(7). Patients at our centre were treated within ≤2 days following presentation with suspicion of MSCC. This represents adherence to national guidelines (NICE) (3) in treating patients within 48hrs of suspicion of MSCC and 24hrs from a confirmed diagnosis (3). Future work will focus on assessing if the reported changes in referrals is to be found in non-specialist centres and district general hospitals across the country. This could help improve resource allocation and capacity across different days of the week depending on demand.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Department of Radiotherapy, University College Hospitals London.

Funding

Has not received any funding.

Disclosure

H.A. Payne: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Astellas; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi Aventis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ferring; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.